<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34696160</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Shooting at a Moving Target-Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1052</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines9101052</ELocationID><Abstract><AbstractText>Since late 2019 the newly emerged pandemic SARS-CoV-2, the causative agent of COVID-19, has hit the world with recurring waves of infections necessitating the global implementation of non-pharmaceutical interventions, including strict social distancing rules, the wearing of masks and the isolation of infected individuals in order to restrict virus transmissions and prevent the breakdown of our healthcare systems. These measures are not only challenging on an economic level but also have a strong impact on social lifestyles. Using traditional and novel technologies, highly efficient vaccines against SARS-CoV-2 were developed and underwent rapid clinical evaluation and approval to accelerate the immunization of the world population, aiming to end the pandemic and return to normality. However, the emergence of virus variants with improved transmission, enhanced fitness and partial immune escape from the first generation of vaccines poses new challenges, which are currently being addressed by scientists and pharmaceutical companies all over the world. In this ongoing pandemic, the evaluation of SARS-CoV-2 vaccines underlies diverse unpredictable dynamics, posed by the first broad application of the mRNA vaccine technology and their compliance, the occurrence of unexpected side effects and the rapid emergence of variations in the viral antigen. However, despite these hurdles, we conclude that the available SARS-CoV-2 vaccines are very safe and efficiently protect from severe COVID-19 and are thereby the most powerful tools to prevent further harm to our healthcare systems, economics and individual lives. This review summarizes the unprecedented pathways of vaccine development and approval during the ongoing SARS-CoV-2 pandemic. We focus on the real-world effectiveness and unexpected positive and negative side effects of the available vaccines and summarize the timeline of the applied adaptations to the recommended vaccination strategies in the light of emerging virus variants. Finally, we highlight upcoming strategies to improve the next generations of SARS-CoV-2 vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xfc;nl</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-4841-4363</Identifier><AffiliationInfo><Affiliation>Institute of Virology (IVM), University of M&#xfc;nster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mecate-Zambrano</LastName><ForeName>Angeles</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2224-5645</Identifier><AffiliationInfo><Affiliation>Institute of Virology (IVM), University of M&#xfc;nster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Centre for Clinical Research (IZKF), Medical Faculty, University of M&#xfc;nster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehl&#xe4;nder</LastName><ForeName>Selina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5452-1384</Identifier><AffiliationInfo><Affiliation>Institute of Virology (IVM), University of M&#xfc;nster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinse</LastName><ForeName>Saskia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University of M&#xfc;nster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludwig</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4490-3052</Identifier><AffiliationInfo><Affiliation>Institute of Virology (IVM), University of M&#xfc;nster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Centre for Clinical Research (IZKF), Medical Faculty, University of M&#xfc;nster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunotte</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University of M&#xfc;nster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Centre for Clinical Research (IZKF), Medical Faculty, University of M&#xfc;nster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BR 5189/1-1</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>CRU342</GrantID><Agency>Clinical Research Unit</Agency><Country/></Grant><Grant><GrantID>01KI20218</GrantID><Agency>Bundesministerium f&#xfc;r Bildung und Forschung</Agency><Country/></Grant><Grant><GrantID>01KX2021</GrantID><Agency>Network University Medicine</Agency><Country/></Grant><Grant><GrantID>Bru2/015/19</GrantID><Agency>Interdisciplinary Centre for Clinical Research (IZKF)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">adverse effects</Keyword><Keyword MajorTopicYN="N">breakthrough infection</Keyword><Keyword MajorTopicYN="N">heterologous vaccination</Keyword><Keyword MajorTopicYN="N">long Covid</Keyword><Keyword MajorTopicYN="N">second generation vaccines</Keyword><Keyword MajorTopicYN="N">vaccine effectiveness</Keyword><Keyword MajorTopicYN="N">vaccine safety</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword><Keyword MajorTopicYN="N">variants</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34696160</ArticleId><ArticleId IdType="pmc">PMC8540924</ArticleId><ArticleId IdType="doi">10.3390/vaccines9101052</ArticleId><ArticleId IdType="pii">vaccines9101052</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jungreis I., Sealfon R., Kellis M. SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes. Nat. Commun. 2021;12 doi: 10.1038/s41467-021-22905-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22905-7</ArticleId><ArticleId IdType="pmc">PMC8113528</ArticleId><ArticleId IdType="pubmed">33976134</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270&#x2013;273. doi: 10.1038/s41586-020-2012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>ZZhou H., Chen X., Hu T., Li J., Song H., Liu Y., Wang P., Liu D., Yang J., Holmes E.C., et al. A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein. Curr. Biol. 2020;30:3896. doi: 10.1016/j.cub.2020.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2020.09.030</ArticleId><ArticleId IdType="pmc">PMC7534657</ArticleId><ArticleId IdType="pubmed">33022232</ArticleId></ArticleIdList></Reference><Reference><Citation>Boni M.F., Lemey P., Jiang X., Lam T.T.-Y., Perry B.W., Castoeet T.A., Rambaut A., Robertson D.L. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat. Microbiol. 2020;5:1408&#x2013;1417. doi: 10.1038/s41564-020-0771-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0771-4</ArticleId><ArticleId IdType="pubmed">32724171</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham R.L., Baric R.S. Recombination, reservoirs, and the modular spike: Mechanisms of coronavirus cross-species transmission. J. Virol. 2010;84:3134&#x2013;3146. doi: 10.1128/JVI.01394-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01394-09</ArticleId><ArticleId IdType="pmc">PMC2838128</ArticleId><ArticleId IdType="pubmed">19906932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lytras S., Hughes J., Martin D., Klerk A., de Lourens R., Pond S.L.K., Xia W., Jiang X., Robertson D.L. Exploring the natural origins of SARS-CoV-2 in the light of recombination. bioRxiv. 2020 doi: 10.1101/2021.01.22.427830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.22.427830</ArticleId><ArticleId IdType="pmc">PMC8882382</ArticleId><ArticleId IdType="pubmed">35137080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam T.T.-Y., Jia N., Zhang Y.-W., Shum M.H.-H., Jiang J.-F., Zhu H.C., Cao W.C. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature. 2020;583:282&#x2013;285. doi: 10.1038/s41586-020-2169-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2169-0</ArticleId><ArticleId IdType="pubmed">32218527</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao K., Zhai J., Feng Y., Zhou N., Zhang X., Zou J.J., Li N., Guo Y., Li X., Shen X., et al. Isolation and characterization of 2019-nCoV-like coronavirus from Malayan pangolins. bioRxiv. 2020 doi: 10.1101/2020.02.17.951335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.02.17.951335</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu Y., McCauley J. GISAID: Global initiative on sharing all influenza data&#x2014;From vision to reality. Eurosurveillance. 2017;22:30494. doi: 10.2807/1560-7917.ES.2017.22.13.30494.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.13.30494</ArticleId><ArticleId IdType="pmc">PMC5388101</ArticleId><ArticleId IdType="pubmed">28382917</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadfield J., Megill C., Bell S.M., Huddleston J., Potter B., Callender C., Sagulenko P., Bedford T., A Neher R. Nextstrain: Real-time tracking of pathogen evolution. Bioinformatics. 2018;34:4121&#x2013;4123. doi: 10.1093/bioinformatics/bty407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty407</ArticleId><ArticleId IdType="pmc">PMC6247931</ArticleId><ArticleId IdType="pubmed">29790939</ArticleId></ArticleIdList></Reference><Reference><Citation>Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G., Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592:116&#x2013;121. doi: 10.1038/s41586-020-2895-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2895-3</ArticleId><ArticleId IdType="pmc">PMC8158177</ArticleId><ArticleId IdType="pubmed">33106671</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M., Marco A., de Lempp F.A., Tortorici M.A., Pinto D., Walls A.C., Beltramello M., Chen A., Liu Z., Zatta F., et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021;184:2332&#x2013;2347.e16. doi: 10.1016/j.cell.2021.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.028</ArticleId><ArticleId IdType="pmc">PMC7962585</ArticleId><ArticleId IdType="pubmed">33761326</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450&#x2013;454. doi: 10.1038/nature02145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02145</ArticleId><ArticleId IdType="pmc">PMC7095016</ArticleId><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., et al. (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Park Y.-J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;183:1735. doi: 10.1016/j.cell.2020.11.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.032</ArticleId><ArticleId IdType="pmc">PMC7833104</ArticleId><ArticleId IdType="pubmed">33306958</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B., Choudhary M.C., Regan J., Sparks J.A., Padera R.F., Qiu X., Solomon I.H., Kuo H.-H., Boucau J., Li J.Z., et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N. Engl. J. Med. 2020;383:2291&#x2013;2293. doi: 10.1056/NEJMc2031364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031364</ArticleId><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Eguia R.T., Crawford K.H.D., Stevens-Ayers T., Kelnhofer-Millevolte L., Greninger A.L., Englund J.A., Boeckh M.J., Bloom J.D. A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 2021;17:e1009453. doi: 10.1371/journal.ppat.1009453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009453</ArticleId><ArticleId IdType="pmc">PMC8031418</ArticleId><ArticleId IdType="pubmed">33831132</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz E., Hill V., McCrone J.T., Price A., Jorgensen D., O&#x2019;Toole &#xc1;., Allan J. Evaluating the effects of SARS-CoV-2 spike mutation D614g on transmissibility and pathogenicity. Cell. 2021;184:64&#x2013;75.e11. doi: 10.1016/j.cell.2020.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.020</ArticleId><ArticleId IdType="pmc">PMC7674007</ArticleId><ArticleId IdType="pubmed">33275900</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., O&#x2019;Toole A., Southgate J., Johnson R., Jackson B., Nascimento F.F., et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 Virus. Cell. 2020;182:812&#x2013;827.e19. doi: 10.1016/j.cell.2020.06.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.043</ArticleId><ArticleId IdType="pmc">PMC7332439</ArticleId><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>Isabel S., Gra&#xf1;a-Miraglia L., Gutierrez J.M., Bundalovic-Torma C., Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T., et al. Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. Sci. Rep. 2020;10:14031. doi: 10.1038/s41598-020-70827-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70827-z</ArticleId><ArticleId IdType="pmc">PMC7441380</ArticleId><ArticleId IdType="pubmed">32820179</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobeil S.M.-C., Janowska K., McDowell S., Mansouri K., Parks R., Manne K., Stalls V., Kopp M.F., Henderson R., Edwards R.J., et al. D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1/S2 junction. Cell Rep. 2021;34:108630. doi: 10.1016/j.celrep.2020.108630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108630</ArticleId><ArticleId IdType="pmc">PMC7762703</ArticleId><ArticleId IdType="pubmed">33417835</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Cai Y., Xiao T., Lu J., Peng H., Sterling S.M., Walsh R.M., Jr., Zhu S.R.-V.H., Woosley A.N., Yang W., et al. Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science. 2021;372:525&#x2013;530. doi: 10.1126/science.abf2303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf2303</ArticleId><ArticleId IdType="pmc">PMC8139424</ArticleId><ArticleId IdType="pubmed">33727252</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman D., Alameh M.-G., Silva T., de Collini P., Hornsby H., Brown R., LaBranche C.C., Edwards R.J., Sutherland L., Santra S., et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe. 2021;29:23&#x2013;31.e4. doi: 10.1016/j.chom.2020.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.11.012</ArticleId><ArticleId IdType="pmc">PMC7707640</ArticleId><ArticleId IdType="pubmed">33306985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozono S., Zhang Y., Ode H., Sano K., Tan T.S., Imai K., Miyoshi K., Kishigami S., Ueno T., Iwatani Y., et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat. Commun. 2021;12:1&#x2013;9. doi: 10.1038/s41467-021-21118-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21118-2</ArticleId><ArticleId IdType="pmc">PMC7870668</ArticleId><ArticleId IdType="pubmed">33558493</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniloski Z., Jordan T.X., Ilmain J.K., Guo X., Bhabha G., tenOever B.R., Sanjana N.E. The spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. eLife. 2021;10:e65365. doi: 10.7554/eLife.65365.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.65365</ArticleId><ArticleId IdType="pmc">PMC7891930</ArticleId><ArticleId IdType="pubmed">33570490</ArticleId></ArticleIdList></Reference><Reference><Citation>Yurkovetskiy L., Wang X., Pascal K.E., Tomkins-Tinch C., Nyalile T.P., Wang Y., Baum A., Diehl W.E., Dauphin A., Carbone C., et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell. 2020;183:739&#x2013;751.e8. doi: 10.1016/j.cell.2020.09.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.032</ArticleId><ArticleId IdType="pmc">PMC7492024</ArticleId><ArticleId IdType="pubmed">32991842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Jackson C.B., Mou H., Ojha A., Peng H., Quinlan B.D., Rangarajan E.S., Pan A., Vanderheiden A., Suthar M.S., et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 2020;11:6013. doi: 10.1038/s41467-020-19808-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19808-4</ArticleId><ArticleId IdType="pmc">PMC7693302</ArticleId><ArticleId IdType="pubmed">33243994</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B., Thao T.T.N., Hoffmann D., Taddeo A., Ebert N., Labroussaa F., Pohlmann A., King J., Steiner S., Kelly J.N., et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature. 2021;592:122&#x2013;127. doi: 10.1038/s41586-021-03361-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03361-1</ArticleId><ArticleId IdType="pubmed">33636719</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H., Leist S.R., Sch&#xe4;fer A., Nakajima N., Takahashi K., et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370:eabe8499. doi: 10.1126/science.abe8499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe8499</ArticleId><ArticleId IdType="pmc">PMC7775736</ArticleId><ArticleId IdType="pubmed">33184236</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.A., Xie X., Bailey A.L., Kalveram B., Lokugamage K.G., Muruato A., Zou J., Zhang X., Juelich T., Smith J.K., et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021;591:293&#x2013;299. doi: 10.1038/s41586-021-03237-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03237-4</ArticleId><ArticleId IdType="pmc">PMC8175039</ArticleId><ArticleId IdType="pubmed">33494095</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito A., Irie T., Suzuki R., Maemura T., Nasser H., Uriu K., Kosugi Y., Shirakawa K., Sadamasu K., Kimura I., et al. SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity. bioRxiv. 2021 doi: 10.1101/2021.06.17.448820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.17.448820</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock T.P., Goldhill D.H., Zhou J., Baillon L., Frise R., Swann O.C., Kugathasan R., Penn R., Brown J.C., Sanchez-David R.Y., et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat. Microbiol. 2021;6:899&#x2013;909. doi: 10.1038/s41564-021-00908-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00908-w</ArticleId><ArticleId IdType="pubmed">33907312</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestle D., Heindl M.R., Limburg H., van Lam T., Pilgram O., Moulton H., Stein D.A., Hardes K., Eickmann M.E., Dolnik O., et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance. 2020;3:e202000786. doi: 10.26508/lsa.202000786.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202000786</ArticleId><ArticleId IdType="pmc">PMC7383062</ArticleId><ArticleId IdType="pubmed">32703818</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., P&#xf6;hlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell. 2020;78:779&#x2013;784.e5. doi: 10.1016/j.molcel.2020.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2020.04.022</ArticleId><ArticleId IdType="pmc">PMC7194065</ArticleId><ArticleId IdType="pubmed">32362314</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock T.P., Penrice-Randal R., Hiscox J.A., Barclay W.S. SARS-CoV-2 one year on: Evidence for ongoing viral adaptation. J. Gen. Virol. 2021;102 doi: 10.1099/jgv.0.001584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001584</ArticleId><ArticleId IdType="pmc">PMC8290271</ArticleId><ArticleId IdType="pubmed">33855951</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman N.S., Fleishon S., Bucris E., Bar-Ilan D., Linial M., Bar-Or I., Indenbaum V., Weil M., Lustig Y., Mendelson E., et al. A unique SARS-CoV-2 spike protein P681H strain detected in Israel. Vaccines. 2021;9:616. doi: 10.3390/vaccines9060616.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9060616</ArticleId><ArticleId IdType="pmc">PMC8228438</ArticleId><ArticleId IdType="pubmed">34201088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubinski B., Tang T., Daniel S., Jaimes J.A., Whittaker G.R. Functional evaluation of proteolytic activation for the SARS-CoV-2 variant B.1.1.7: Role of the P681H mutation. bioRxiv. 2021 doi: 10.1101/2021.04.06.438731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.06.438731</ArticleId><ArticleId IdType="pmc">PMC8662955</ArticleId><ArticleId IdType="pubmed">34909610</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheepers C., Everatt J., Amoako D.G., Mnguni A., Ismail A., Mahlangu B., Wibmer C.K., Wilkinson E., Tegally H., San J.E., et al. The Continuous Evolution of SARS-CoV-2 in South Africa: A New Lineage with Rapid Accumulation of Mutations of Concern and Global Detection. medRxiv. 2021 doi: 10.1101/2021.08.20.21262342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.08.20.21262342</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveca F.G., Nascimento V., Souza V., Corado A., Nascimento F., Silva G., Mej&#xed;a M., Costa &#xc1;., Duarte D., Pessoa K., et al.  Emergence and Spread of SARS-CoV-2 P.1 (Gamma) Lineage Variants Carrying Spike Mutations del141-144, N679K or P681H during Persistent Viral Circulation in Amazonas, Brazil&#x2014;SARS-CoV-2 Coronavirus/nCoV-2019 Genomic Epidemiology&#x2014;Virological. 2021.  [(accessed on 13 September 2021)].  Available online:  https://virological.org/t/emergence-and-spread-of-sars-cov-2-p-1-gamma-lineage-variants-carrying-spike-mutations-141-144-n679k-or-p681h-during-persistent-viral-circulation-in-amazonas-brazil/722.</Citation></Reference><Reference><Citation>Cheng M.H., Krieger J.M., Kaynak B., Arditi M., Bahar I. Impact of South African 501.V2 variant on SARS-CoV-2 spike infectivity and neutralization: A structure-based computational assessment. bioRxiv. 2021 doi: 10.1101/2021.01.10.426143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.10.426143</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W., Zhou D., Supasa P., Liu C., Mentzer A.J., Ginn H.M., Zhao Y., Duyvesteyn H.M.E., Tuekprakhon A., Nutalai R., et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021;184:2939&#x2013;2954.e9. doi: 10.1016/j.cell.2021.03.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.055</ArticleId><ArticleId IdType="pmc">PMC8008340</ArticleId><ArticleId IdType="pubmed">33852911</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Casner R.G., Nair M.S., Wang M., Yu J., Cerutti G., Liu L., Kwong P.D., Huang Y., Shapiro L., et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. bioRxiv. 2021 doi: 10.1101/2021.03.01.433466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.01.433466</ArticleId><ArticleId IdType="pmc">PMC8053237</ArticleId><ArticleId IdType="pubmed">33887205</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X., Liu Y., Liu J., Zhang X., Zou J., Fontes-Garfias C.R., Xia H., Swanson K.A., Cutler M., Cooper D., et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 2021;27:620&#x2013;621. doi: 10.1038/s41591-021-01270-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01270-4</ArticleId><ArticleId IdType="pubmed">33558724</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A.J., Starr T.N., Gilchuk P., Zost S.J., Binshtein E., Loes A.N., Hilton S.K., Huddleston J., Eguia R., Crawford K.H.D., et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2021;29:44&#x2013;57.e9. doi: 10.1016/j.chom.2020.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7676316</ArticleId><ArticleId IdType="pubmed">33259788</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A.J., Loes A.N., Crawford K.H., Starr T.N., Malone K.D., Chu H.Y., Bloom J.D. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29:463&#x2013;476.e6. doi: 10.1016/j.chom.2021.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.02.003</ArticleId><ArticleId IdType="pmc">PMC7869748</ArticleId><ArticleId IdType="pubmed">33592168</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., St Denis, K.; Nitido, A.D.; Garcia, Z.H.; Hauser, B.M.; Feldman, J.; Pavlovic, M.N.; Gregory, D.J.; Poznansky, M.C.; et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372&#x2013;2383.e9. doi: 10.1016/j.cell.2021.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC7953441</ArticleId><ArticleId IdType="pubmed">33743213</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum Y., Schmidt F., Zhang F., DaSilva J., Poston D., Lorenzi J.C.C., Muecksch F., Rutkowska M., Hoffmann H.-H., Michailidis E., et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020;9 doi: 10.7554/eLife.61312. preprint.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.61312</ArticleId><ArticleId IdType="pmc">PMC7723407</ArticleId><ArticleId IdType="pubmed">33112236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Arora P., Gro&#xdf; R., Seidel A., H&#xf6;rnich B., Hahn A., Kr&#xfc;ger N., Graichen L., Hofmann-Winkler H., Kempf A., et al. SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination. Cell. 2021;181:271&#x2013;280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J.C., Goldhill D.H., Zhou J., Peacock T.P., Frise R., Goonawardane N., Baillon L., Kugathasan R., Pinto A.L., McKay P.F., et al. Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape. bioRxiv. 2021 doi: 10.1101/2021.02.24.432576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.24.432576</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V., Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020 doi: 10.1101/2020.12.21.20248640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.21.20248640</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria N.R., Mellan T.A., Whittaker C., Claro I.M., Da Candido D.S., Mishra S., Crispim M.A.E., Sales F.C.S., Hawryluk I., McCrone J.T., et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372:815&#x2013;821. doi: 10.1126/science.abh2644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh2644</ArticleId><ArticleId IdType="pmc">PMC8139423</ArticleId><ArticleId IdType="pubmed">33853970</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria N.R., Claro I.M., Candido D., Franco L.A.M., Andrade P.S., Coletti T.M., Silva C.A.M., Sales F.C.S., Manuli E.R., Aguiar R.S., et al.  Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in Manaus: Preliminary Findings&#x2014;SARS-CoV-2 Coronavirus / nCoV-2019 Genomic Epidemiology&#x2014;Virological. 2021.  [(accessed on 20 August 2021)].  Available online:  https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586.</Citation></Reference><Reference><Citation>Zhao S., Lou J., Cao L., Zheng H., Chong M.K.C., Chen Z., Chan R.W.Y., Zee B.C.Y., Chan P.K.S., Wang M.H. Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the UK: An early data-driven analysis. J. Travel Med. 2021;28 doi: 10.1093/jtm/taab011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taab011</ArticleId><ArticleId IdType="pmc">PMC7928809</ArticleId><ArticleId IdType="pubmed">33506254</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung K., Shum M.H.H., Leung G.M., Lam T.T.Y., Wu J.T. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Eurosurveillance. 2021;26:2002106. doi: 10.2807/1560-7917.ES.2020.26.1.2002106.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.26.1.2002106</ArticleId><ArticleId IdType="pmc">PMC7791602</ArticleId><ArticleId IdType="pubmed">33413740</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies N.G., Abbott S., Barnard R.C., Jarvis C.I., Kucharski A.J., Munday J.D., Pearson C.A.B., Russell T.W., Tully D.C., Washburne A.D., et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055. doi: 10.1126/science.abg3055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg3055</ArticleId><ArticleId IdType="pmc">PMC8128288</ArticleId><ArticleId IdType="pubmed">33658326</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Greaney A.J., Hilton S.K., Ellis D., Crawford K.H., Dingens A.S., Navarro M.J., Bowen J.E., Tortorici M.A., Walls A.C., et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020;182:1295&#x2013;1310.e20. doi: 10.1016/j.cell.2020.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.012</ArticleId><ArticleId IdType="pmc">PMC7418704</ArticleId><ArticleId IdType="pubmed">32841599</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton M.I., MacGowan S., Kutuzov M., Dushek O., Barton G.J., van der Merwe P.A. Effects of common mutations in the SARS-CoV-2 Spike RBD domain and its ligand the human ACE2 receptor on binding affinity and kinetics. bioRxiv. 2021 doi: 10.1101/2021.05.18.444646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.18.444646</ArticleId><ArticleId IdType="pmc">PMC8480977</ArticleId><ArticleId IdType="pubmed">34435953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez E., Haycroft E.R., Adair A., Mordant F.L., O&#x2019;Neill M.T., Pymm P., Chung A.W. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants with a novel competitive multiplex assay. medRxiv. 2021 doi: 10.1101/2021.03.20.21254037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.20.21254037</ArticleId><ArticleId IdType="pmc">PMC8409985</ArticleId><ArticleId IdType="pubmed">34251356</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X., Zou J., Fontes-Garfias C.R., Xia H., Swanson K.A., Cutler M., Cooper D., Menachery V., Weaver S., Dormitzer P. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. Res. Sq. 2021 doi: 10.21203/rs.3.rs-143532/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-143532/v1</ArticleId><ArticleId IdType="pubmed">33558724</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes W.A., Kamath K., Lucas C., Shon J., Iwasaki A. Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes. medRxiv. 2021 doi: 10.1101/2021.01.06.20248960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.06.20248960</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson E.C., Rosen L.E., Shepherd J.G., Spreafico R., Filipe A.D.S., Wojcechowskyj J.A., Davis C., Piccoli L., Pascall D.J., Dillen J., et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021;184:1171&#x2013;1187.e20. doi: 10.1016/j.cell.2021.01.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.037</ArticleId><ArticleId IdType="pmc">PMC7843029</ArticleId><ArticleId IdType="pubmed">33621484</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Greaney A.J., Addetia A., Hannon W.W., Choudhary M.C., Dingens A.S., Li J.Z., Bloom J.D. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. bioRxiv. 2020 doi: 10.1101/2020.11.30.405472. Preprint.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.30.405472</ArticleId><ArticleId IdType="pmc">PMC7963219</ArticleId><ArticleId IdType="pubmed">33495308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Schmidt F., Weisblum Y., Muecksch F., Barnes C.O., Finkin S., Schaefer-Babajew D., Cipolla M., Gaebler C., Lieberman J.A., et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. bioRxiv. 2021 doi: 10.1101/2021.01.15.426911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.15.426911</ArticleId><ArticleId IdType="pmc">PMC8503938</ArticleId><ArticleId IdType="pubmed">33567448</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Czudnochowski N., Liu Z., Zatta F., Park Y.-J., Addetia A., Pinto D., Beltramello M., Hernandez P., Greaney A.J., et al. SARS-CoV-2 RBD Antibodies that Maximize Breadth and Resistance to Escape. Nature. 2021;597:97&#x2013;102. doi: 10.1038/s41586-021-03807-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03807-6</ArticleId><ArticleId IdType="pmc">PMC9282883</ArticleId><ArticleId IdType="pubmed">34261126</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A.J., Starr T.N., Barnes C.O., Weisblum Y., Schmidt F., Caskey M., Gaebler C., Cho A., Agudelo M., Finkin S., et al. Mapping Mutations to the SARS-CoV-2 RBD that Escape Binding by Different Classes of Antibodies. Nat. Commun. 2021;12:4196. doi: 10.1038/s41467-021-24435-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24435-8</ArticleId><ArticleId IdType="pmc">PMC8263750</ArticleId><ArticleId IdType="pubmed">34234131</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Greaney A.J., Dingens A.S., Bloom J.D. Complete Map of SARS-CoV-2 RBD Mutations that Escape the Monoclonal Antibody LY-CoV555 and Its Cocktail with LY-CoV016. Cell Rep. Med. 2021;2:100255. doi: 10.1016/j.xcrm.2021.100255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100255</ArticleId><ArticleId IdType="pmc">PMC8020059</ArticleId><ArticleId IdType="pubmed">33842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom J.D. Sites in SARS-CoV-2 RBD Where Mutations Reduce Binding by Antibodies/Sera. 2021.  [(accessed on 13 September 2021)].  Available online:  https://jbloomlab.github.io/SARS2_RBD_Ab_escape_maps/</Citation></Reference><Reference><Citation>Wise J. Covid-19: The E484K mutation and the risks it poses. BMJ. 2021;372:n359. doi: 10.1136/bmj.n359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n359</ArticleId><ArticleId IdType="pubmed">33547053</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P., Kemp S., Dhar M.S., Papa G., Meng B., Mishra S., Whittaker C., Mellan T., Ferreira I., Datir R., et al. SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough. bioRxiv. 2021 doi: 10.1101/2021.05.08.443253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.08.443253</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum Y., Schmidt F., Zhang F., DaSilva J., Poston D., Lorenzi J.C., Muecksch F., Rutkowska M., Hoffmann H.-H., Michailidis E., et al. Escape from Neutralizing Antibodies by SARS-CoV-2 Spike Protein Variants. eLife. 2020;9:e61312. doi: 10.7554/eLife.61312.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.61312</ArticleId><ArticleId IdType="pmc">PMC7723407</ArticleId><ArticleId IdType="pubmed">33112236</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen B., Luebke N., Feldt T., Keitel V., Brandenburger T., Kindgen-Milles D., Lutterbeck M., Freise N.F., Schoeler D., Haas R., et al. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. Lancet Reg. Health Eur. 2021;8:100164. doi: 10.1016/j.lanepe.2021.100164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100164</ArticleId><ArticleId IdType="pmc">PMC8278033</ArticleId><ArticleId IdType="pubmed">34278371</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X., Garcia-Knight M.A., Khalid M.M., Servellita V., Wang C., Morris M.K., Sotomayor-Gonz&#xe1;lez A., Glasner D.R., Reyes K.R., Gliwa A.S., et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021;184:3426&#x2013;3437.e8. doi: 10.1016/j.cell.2021.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.04.025</ArticleId><ArticleId IdType="pmc">PMC8057738</ArticleId><ArticleId IdType="pubmed">33991487</ArticleId></ArticleIdList></Reference><Reference><Citation>Motozono C., Toyoda M., Zahradnik J., Ikeda T., Saito A., Tan T.S., Ngare I., Nasser H., Kimura I., Uriu K., et al. An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity. bioRxiv. 2021 doi: 10.1101/2021.04.02.438288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.02.438288</ArticleId></ArticleIdList></Reference><Reference><Citation>Conceicao C., Thakur N., Human S., Kelly J.T., Logan L., Bialy D., Bhat S., Stevenson-Leggett P., Zagrajek A.K., Hollinghurst P., et al. The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. PLoS Biol. 2020;18:e3001016. doi: 10.1371/journal.pbio.3001016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001016</ArticleId><ArticleId IdType="pmc">PMC7751883</ArticleId><ArticleId IdType="pubmed">33347434</ArticleId></ArticleIdList></Reference><Reference><Citation>Welkers M.R.A., Han A.X., Reusken C.B.E.M., Eggink D. Possible host-adaptation of SARS-CoV-2 due to improved ACE2 receptor binding in mink. Virus Evol. 2021;7 doi: 10.1093/ve/veaa094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veaa094</ArticleId><ArticleId IdType="pmc">PMC7798643</ArticleId><ArticleId IdType="pubmed">33500787</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M., Bassi J., Marco A., de Chen A., Walls A.C., Di Iulio J., Tortorici M.A., Navarro M.-J., Silacci-Fregni C., Saliba C., et al. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv. 2021 doi: 10.1101/2021.03.31.437925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.31.437925</ArticleId><ArticleId IdType="pmc">PMC9835956</ArticleId><ArticleId IdType="pubmed">34210893</ArticleId></ArticleIdList></Reference><Reference><Citation>Avanzato V.A., Matson M.J., Seifert S.N., Pryce R., Williamson B.N., Anzick S.L., Barbian K., Judson S.D., Fischer E.R., Martens C., et al. Case study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183:1901&#x2013;1912.e9. doi: 10.1016/j.cell.2020.10.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.049</ArticleId><ArticleId IdType="pmc">PMC7640888</ArticleId><ArticleId IdType="pubmed">33248470</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy K.R., Rennick L.J., Nambulli S., Robinson-McCarthy L.R., Bain W.G., Haidar G., Duprex W.P. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science. 2021;371:1139&#x2013;1142. doi: 10.1126/science.abf6950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf6950</ArticleId><ArticleId IdType="pmc">PMC7971772</ArticleId><ArticleId IdType="pubmed">33536258</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M. Site-Specific Glycan Analysis of the SARS-CoV-2 Spike. Volume 369. Science; New York, NY, USA: 2021. pp. 330&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199903</ArticleId><ArticleId IdType="pubmed">32366695</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici M.A., Beltramello M., Lempp F.A., Pinto D., Dang H.V., Rosen L.E., McCallum M., Bowen J., Minola A., Jaconi S., et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science. 2020;370:950&#x2013;957. doi: 10.1126/science.abe3354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe3354</ArticleId><ArticleId IdType="pmc">PMC7857395</ArticleId><ArticleId IdType="pubmed">32972994</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli L., Park Y.-J., Tortorici M.A., Czudnochowski N., Walls A.C., Beltramello M., Silacci-Fregni C., Pinto D., Rosen L.E., Bowen J.E., et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183:1024&#x2013;1042.e21. doi: 10.1016/j.cell.2020.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.037</ArticleId><ArticleId IdType="pmc">PMC7494283</ArticleId><ArticleId IdType="pubmed">32991844</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S., Harvey W.T., Lytras S., Mohamed A., Gallo G., et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 2021;35:109292. doi: 10.1016/j.celrep.2021.109292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109292</ArticleId><ArticleId IdType="pmc">PMC8185188</ArticleId><ArticleId IdType="pubmed">34166617</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp S.A., Collier D.A., Datir R.P., Ferreira I.A.T.M., Gayed S., Jahun A., Hosmillo M., Rees-Spear C., Mlcochova P., Lumb I.U., et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592:277&#x2013;282. doi: 10.1038/s41586-021-03291-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03291-y</ArticleId><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F., Strohmeier S., Rathnasinghe R., Schotsaert M., Coughlan L., Garc&#xed;a-Sastre A., Krammer F. Introduction of two prolines and removal of the polybasic cleavage site lead to higher efficacy of a recombinant spike-based SARS-CoV-2 vaccine in the mouse model. mBio. 2021;12:e02648-20. doi: 10.1128/mBio.02648-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02648-20</ArticleId><ArticleId IdType="pmc">PMC8092267</ArticleId><ArticleId IdType="pubmed">33653892</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C.-L., Goldsmith J.A., Schaub J.M., DiVenere A.M., Kuo H.-C., Javanmardi K., Le K.C., Wrapp D., Lee A.G.-W., Liu Y., et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020;369:1501&#x2013;1505. doi: 10.1126/science.abd0826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0826</ArticleId><ArticleId IdType="pmc">PMC7402631</ArticleId><ArticleId IdType="pubmed">32703906</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercado N.B., Zahn R., Wegmann F., Loos C., Chandrashekar A., Yu J., Liu J., Peter L., McMahan K., Tostanoski L.H., et al. Single-Shot Ad26 Vaccine Protects against SARS-CoV-2 in Rhesus Macaques. Nature. 2020;586:583&#x2013;588. doi: 10.1038/s41586-020-2607-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2607-z</ArticleId><ArticleId IdType="pmc">PMC7581548</ArticleId><ArticleId IdType="pubmed">32731257</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J.-H., Patel N., Haupt R., Zhou H., Weston S., Hammond H., Logue J., Portnoff A.D., Norton J., Guebre-Xabier M., et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 2021;12:372. doi: 10.1038/s41467-020-20653-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20653-8</ArticleId><ArticleId IdType="pmc">PMC7809486</ArticleId><ArticleId IdType="pubmed">33446655</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R.R., Apostolidis S.A., Painter M.M., Mathew D., Pattekar A., Kuthuru O., Gouma S., Kuri-Cervantes L., Meng W., Adamski S., et al. Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Na&#xef;ve and Recovered Individuals Following mRNA Vaccination. medRxiv. 2021 doi: 10.1101/2021.03.03.21252872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.03.21252872</ArticleId><ArticleId IdType="pmc">PMC8158969</ArticleId><ArticleId IdType="pubmed">33858945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer K., Casta&#xf1;o D., Atria D.G., Oguin T.H., Wang S., Manzoni T.B., Muramatsu H., Hogan M.J., Amanat F., Cherubin P., et al. SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity. 2020;53:1281&#x2013;1295.e5. doi: 10.1016/j.immuni.2020.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.11.009</ArticleId><ArticleId IdType="pmc">PMC7680029</ArticleId><ArticleId IdType="pubmed">33296685</ArticleId></ArticleIdList></Reference><Reference><Citation>Mades A., Chellamathu P., Lopez L., Kojima N., MacMullan M.A., Denny N., Angel A.N., Casian J.G., Brobeck M., Nirema N., et al. Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination. medRxiv. 2021 doi: 10.1101/2021.05.06.21256403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.06.21256403</ArticleId><ArticleId IdType="pmc">PMC8712521</ArticleId><ArticleId IdType="pubmed">34961780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ketas T.J., Chaturbhuj D., Cruz-Portillo V.M., Francomano E., Golden E., Chandrasekhar S., Debnath G., D&#xed;az-Tapia R., Yasmeen A., Kramer K.D., et al. Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. Pathog. Immun. 2021;6:116. doi: 10.20411/pai.v6i1.441.</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v6i1.441</ArticleId><ArticleId IdType="pmc">PMC8201795</ArticleId><ArticleId IdType="pubmed">34136730</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro J.R., Farber D.L. COVID-19 vaccines: Modes of immune activation and future challenges. Nat. Rev. Immunol. 2021;21:195&#x2013;197. doi: 10.1038/s41577-021-00526-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00526-x</ArticleId><ArticleId IdType="pmc">PMC7934118</ArticleId><ArticleId IdType="pubmed">33674759</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-Etayo F.J., Su&#xe0;rez-Fern&#xe1;ndez P., Cabrera-Marante O., Arroyo D., Garcinu&#xf1;o S., Naranjo L., Pleguezuelo D.E., Allende L.M., Mancebo E., Lalueza A., et al. T-Helper Cell Subset Response Is A Determining Factor in COVID-19 Progression. Front. Cell. Infect. Microbiol. 2021;11:624483. doi: 10.3389/fcimb.2021.624483.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.624483</ArticleId><ArticleId IdType="pmc">PMC7952877</ArticleId><ArticleId IdType="pubmed">33718270</ArticleId></ArticleIdList></Reference><Reference><Citation>Moderbacher C.R., Ramirez S.I., Dan J.M., Grifoni A., Hastie K.M., Weiskopf D., Belanger S., Abbott R.K., Kim C., Choi J., et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020;183:996&#x2013;1012.e19. doi: 10.1016/j.cell.2020.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U., Muik A., Derhovanessian E., Vogler I., Kranz L.M., Vormehr M., Baum A., Pascal K., Quandt J., Maurus D., et al. COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses. Nature. 2020;586:594&#x2013;599. doi: 10.1038/s41586-020-2814-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2814-7</ArticleId><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., Grifoni A., Ramirez S.I., Haupt S., Frazier A., et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. doi: 10.1126/science.abf4063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberhardt V., Luxenburger H., Kemming J., Schulien I., Ciminski K., Giese S., Csernalabics B., Lang-Meli J., Janowska I., Staniek J., et al. Rapid and Stable Mobilization of CD8+ T Cells by SARS-CoV-2 mRNA Vaccine. Nature. 2021;597:268&#x2013;273. doi: 10.1038/s41586-021-03841-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03841-4</ArticleId><ArticleId IdType="pmc">PMC8426185</ArticleId><ArticleId IdType="pubmed">34320609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J., Dowell A.C., Pearce H., Verma K., Long H.M., Begum J., Aiano F., Amin-Chowdhury Z., Hoschler K., Brooks T., et al. Robust SARS-CoV-2-Specific T Cell Immunity is Maintained at 6 Months Following Primary Infection. Nat. Immunol. 2021;22:620&#x2013;626. doi: 10.1038/s41590-021-00902-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00902-8</ArticleId><ArticleId IdType="pmc">PMC7610739</ArticleId><ArticleId IdType="pubmed">33674800</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervina A.A., Pogorelyy M.V., Kirk A.M., Allen E.K., Allison K.J., Lin C.-Y., Brice D.C., Zhu X., Vegesana K., Wu G., et al. Convergent epitope-specific T cell responses after SARS-CoV-2 infection and vaccination. medRxiv. 2021 doi: 10.1101/2021.07.12.21260227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.12.21260227</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel A.B., Kanevsky I., Che Y., Swanson K.A., Muik A., Vormehr M., Kranz L.M., Walzer K.C., Hein S., G&#xfc;ler A., et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592:283&#x2013;289. doi: 10.1038/s41586-021-03275-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03275-y</ArticleId><ArticleId IdType="pubmed">33524990</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C., Sharma A.R., Bhattacharya M., Lee S.-S. From COVID-19 to Cancer mRNA vaccines: Moving from bench to clinic in the vaccine landscape. Front. Immunol. 2021;12:679344. doi: 10.3389/fimmu.2021.679344.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.679344</ArticleId><ArticleId IdType="pmc">PMC8293291</ArticleId><ArticleId IdType="pubmed">34305909</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh E.E., Frenck R.W., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 2020;383:2439&#x2013;2450. doi: 10.1056/NEJMoa2027906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., P&#xe9;rez Marc G., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Roser M., Ritchie H., Ortiz-Ospina E., Hasell J., Coronavirus Pandemic (COVID-19)  Our World in Data.  [(accessed on 14 September 2021)].  Available online:  https://ourworldindata.org/coronavirus.</Citation></Reference><Reference><Citation>Haas E.J., Angulo F.J., McLaughlin J.M., Anis E., Singer S.R., Khan F., Brooks N., Smaja M., Mircus G., Pan K., et al. Impact and Effectiveness of mRNA BNT162b2 Vaccine against SARS-CoV-2 Infections and COVID-19 Cases, Hospitalisations, and Deaths Following a Nationwide Vaccination Campaign in Israel: An Observational Study Using National Surveillance data. Lancet. 2021;397:1819&#x2013;1829. doi: 10.1016/S0140-6736(21)00947-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00947-8</ArticleId><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N., Barda N., Kepten E., Miron O., Perchik S., Katz M.A., Hern&#xe1;n M.A., Lipsitch M., Reis B., Balicer R.D. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N. Engl. J. Med. 2021;384:1412&#x2013;1423. doi: 10.1056/NEJMoa2101765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101765</ArticleId><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rk J., Inghammar M., Moghaddassi M., Rasmussen M., Malmqvist U., Kahn F. Effectiveness of the BNT162b2 Vaccine in Preventing COVID-19 in the Working Age Population&#x2014;First Results from A Cohort Study in Southern Sweden. medRxiv. 2021 doi: 10.1101/2021.04.20.21254636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.20.21254636</ArticleId><ArticleId IdType="pmc">PMC8500302</ArticleId><ArticleId IdType="pubmed">34586934</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum U., Poukka E., Palmu A.A., Salo H., Lehtonen T.O., Kahn F. Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill&#x2014;An interim analysis of a nationwide cohort study. medRxiv. 2021 doi: 10.1101/2021.06.21.21258686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.21.21258686</ArticleId><ArticleId IdType="pmc">PMC8601574</ArticleId><ArticleId IdType="pubmed">34793476</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal K.G., Freeman E.E., Saff R.R., Robinson L.B., Wolfson A.R., Foreman R.K., Hashimoto D., Banerji A., Li L., Anvari S., et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N. Engl. J. Med. 2021;384:1273&#x2013;1277. doi: 10.1056/NEJMc2102131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2102131</ArticleId><ArticleId IdType="pmc">PMC7944952</ArticleId><ArticleId IdType="pubmed">33657292</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson M.G., Burgess J.L., Naleway A.L., Tyner H.L., Yoon S.K., Foreman R.K., Hashimoto D., Banerji A., Li L., Anvari S., et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers&#x2014;Eight U.S. locations, December 2020&#x2013;March 2021. MMWR Morb. Mortal. Wkly. Report. 2021;70:495&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8022879</ArticleId><ArticleId IdType="pubmed">33793460</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin E. COVID-19 Vaccines Poised for Launch, But Impact on Pandemic Unclear. Nat. Biotech. 2020 doi: 10.1038/d41587-020-00022-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41587-020-00022-y</ArticleId><ArticleId IdType="pubmed">33239758</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Liu J., Xia H., Zhang X., Fontes-Garfias C.R., Swanson K.A., Cai H., Sarkar R., Chen W., Cutler M., et al. Neutralizing activity of BNT162b2-elicited serum. N. Engl. J. Med. 2021;384:1466&#x2013;1468. doi: 10.1056/NEJMc2102017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2102017</ArticleId><ArticleId IdType="pmc">PMC7944950</ArticleId><ArticleId IdType="pubmed">33684280</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad L.J., Chemaitelly H., Butt A.A. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. 2021;385:187&#x2013;189. doi: 10.1056/NEJMc2104974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2104974</ArticleId><ArticleId IdType="pmc">PMC8117967</ArticleId><ArticleId IdType="pubmed">33951357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal J.L., Andrews N., Gower C., Gallagher E., Simmons R., Thelwall S., Stowe J., Tessier E., Groves N., Dabrera G., et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 2021;385:585&#x2013;594. doi: 10.1056/NEJMoa2108891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108891</ArticleId><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreen S., Chung H., He S., Brown K.A., Gubbay J.B., Buchan S.A., Fell D.B., Austin P.C., Schwartz K.L., Sundaram M.E., et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv. 2021 doi: 10.1101/2021.06.28.21259420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.28.21259420</ArticleId></ArticleIdList></Reference><Reference><Citation>Charmet T., Schaeffer L., Grant R., Galmiche S., Ch&#xe9;ny O., Platen C.V., Maurizot A., Rogoff A., Omar F., David C., et al. Impact of Original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 Lineages on Vaccine Effectiveness of Two Doses of COVID-19 mRNA Vaccines: Results from a Nationwide Case-Control Study in France. Lancet Reg. Health Eur. 2021;8:100171. doi: 10.1016/j.lanepe.2021.100171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100171</ArticleId><ArticleId IdType="pmc">PMC8277121</ArticleId><ArticleId IdType="pubmed">34278372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K., Werner A.P., Koch M., Choi A., Narayanan E., Stewart-Jones G.B., Colpitts T., Bennett H., Boyoglu-Barnum S., Shi W., et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N. Engl. J. Med. 2021;384:1468&#x2013;1470. doi: 10.1056/NEJMc2102179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2102179</ArticleId><ArticleId IdType="pmc">PMC8008744</ArticleId><ArticleId IdType="pubmed">33730471</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Yassine H.M., Benslimane F.M., Al Khatib H.A., Tang P., Hasan M.R., Malek J.A., Coyle P., Ayoub H.H., Kanaani Z.A., et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat. Med. 2021;27:1614&#x2013;1621. doi: 10.1038/s41591-021-01446-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01446-y</ArticleId><ArticleId IdType="pubmed">34244681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg E.S., Holtgrave D.R., Dorabawila V., Conroy M., Greene D., Lutterloh E., Backenson B., Hoefer D., Morne J., Bauer U., et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status&#x2014;New York, May 3&#x2013;July 25, 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70 doi: 10.15585/mmwr.mm7037a7.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7037a7</ArticleId><ArticleId IdType="pmc">PMC8445378</ArticleId><ArticleId IdType="pubmed">34529645</ArticleId></ArticleIdList></Reference><Reference><Citation>Moderna, Inc.  Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India|Moderna, Inc. 2021.  [(accessed on 3 July 2021)].  Available online:  https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-clinical-update-neutralizing-activity-its-covid.</Citation></Reference><Reference><Citation>Sheikh A., McMenamin J., Taylor B., Robertson C. SARS-CoV-2 Delta VOC in Scotland: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness. Lancet. 2021;397:2461&#x2013;2462. doi: 10.1016/S0140-6736(21)01358-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01358-1</ArticleId><ArticleId IdType="pmc">PMC8201647</ArticleId><ArticleId IdType="pubmed">34139198</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanduri S., Pilishvili T., Derado G., Soe M.M., Dollard P., Wu H., Li Q., Bagchi S., Dubendris H., Link-Gelles R., et al. Effectiveness of pfizer-BioNTech and moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant&#x2014;National healthcare safety network, March 1&#x2013;August 1, 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1163&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389386</ArticleId><ArticleId IdType="pubmed">34437519</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira T., de Lutucuta S., Nkengasong J., Morais J., Paix&#xe3;o J.P., Neto Z., Afonso P., Miranda J., David K., Ingl&#xea;s L., et al. A Novel Variant of Interest of SARS-CoV-2 with Multiple Spike Mutations Detected through Travel Surveillance in Africa. medRxiv. 2021 doi: 10.1101/2021.03.30.21254323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.30.21254323</ArticleId></ArticleIdList></Reference><Reference><Citation>Uriu K., Kimura I., Shirakawa K., Takaori-Kondo A., Nakada T., Kaneda A., Nakagawa S., Sato K. Ineffective Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Sera. bioRxiv. 2021 doi: 10.1101/2021.09.06.459005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.09.06.459005</ArticleId><ArticleId IdType="pmc">PMC8609602</ArticleId><ArticleId IdType="pubmed">34731554</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal K.G., Robinson L.B., Camargo C.A., Shenoy E.S., Banerji A., Landman A.B., Wickner P. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021;325:1562&#x2013;1565. doi: 10.1001/jama.2021.3976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3976</ArticleId><ArticleId IdType="pmc">PMC7941251</ArticleId><ArticleId IdType="pubmed">33683290</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosner C.M., Genovese L., Tehrani B.N., Atkins M., Bakhshi H., Chaudhri S., Damluji A.A., de Lemos J.A., Desai S.S., Emaminia A., et al. Myocarditis temporally associated with COVID-19 vaccination. Circulation. 2021;144:502&#x2013;505. doi: 10.1161/CIRCULATIONAHA.121.055891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.055891</ArticleId><ArticleId IdType="pmc">PMC8340723</ArticleId><ArticleId IdType="pubmed">34133885</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatsis N., Ertl H.C.J. Adenoviruses as vaccine vectors. Mol. Ther. J. Am. Soc. Gene Ther. 2004;10:616&#x2013;629. doi: 10.1016/j.ymthe.2004.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2004.07.013</ArticleId><ArticleId IdType="pmc">PMC7106330</ArticleId><ArticleId IdType="pubmed">15451446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer E.J. Pros and cons of adenovirus-based SARS-CoV-2 vaccines. Mol. Ther. J. Am. Soc. Gene Ther. 2020;28:2303&#x2013;2304. doi: 10.1016/j.ymthe.2020.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.10.002</ArticleId><ArticleId IdType="pmc">PMC7546260</ArticleId><ArticleId IdType="pubmed">33065038</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchbinder S.P., McElrath M.J., Dieffenbach C., Corey L. Use of adenovirus type-5 vectored vaccines: A cautionary tale. Lancet. 2020;396:e68&#x2013;e69. doi: 10.1016/S0140-6736(20)32156-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32156-5</ArticleId><ArticleId IdType="pmc">PMC7571904</ArticleId><ArticleId IdType="pubmed">33091364</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharbi N.K., Qasim I., Almasoud A., Aljami H.A., Alenazi M.W., Alhafufi A., Aldibasi O.S., Hashem A.M., Kasem S., Albrahim R., et al. Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels. Sci. Rep. 2019;9:16292. doi: 10.1038/s41598-019-52730-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-52730-4</ArticleId><ArticleId IdType="pmc">PMC6841732</ArticleId><ArticleId IdType="pubmed">31705137</ArticleId></ArticleIdList></Reference><Reference><Citation>Antrobus R.D., Coughlan L., Berthoud T.K., Dicks M., Hill A.V., Lambe T., Gilbert S.C. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A Antigens. Mol. Ther. J. Am. Soc.Gene Ther. 2014;22:668&#x2013;674. doi: 10.1038/mt.2013.284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.284</ArticleId><ArticleId IdType="pmc">PMC3944330</ArticleId><ArticleId IdType="pubmed">24374965</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Camacho C., Lorenzo G., de Slon-Campos J.L., Dowall S., Abbink P., Larocca R.A., Kim Y.C., Poggianella M., Graham V., Findlay-Wilson S., et al. Immunogenicity and efficacy of zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines. Vaccines. 2020;8:307. doi: 10.3390/vaccines8020307.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8020307</ArticleId><ArticleId IdType="pmc">PMC7350260</ArticleId><ArticleId IdType="pubmed">32560145</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99&#x2013;111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet. 2021;397:881&#x2013;891. doi: 10.1016/S0140-6736(21)00432-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00432-3</ArticleId><ArticleId IdType="pmc">PMC7894131</ArticleId><ArticleId IdType="pubmed">33617777</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doremalen N., Purushotham J.N., Schulz J.E., Holbrook M.G., Bushmaker T., Carmody A., Port J.R., Yinda C.K., Okumura A., Saturday G., et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques. bioRxiv. 2021 doi: 10.1101/2021.01.09.426058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.09.426058</ArticleId><ArticleId IdType="pmc">PMC9267380</ArticleId><ArticleId IdType="pubmed">34315826</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671&#x2013;681. doi: 10.1016/S0140-6736(21)00234-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00234-8</ArticleId><ArticleId IdType="pmc">PMC7852454</ArticleId><ArticleId IdType="pubmed">33545094</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray M.L., Shukarev G., Heerwegh D., Truyers C., de Groot A.M., Stoop J., Tete S., Van Damme W., Leroux-Roels I., et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 2021;384:2187&#x2013;2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M., et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014&#x2013;1018. doi: 10.1126/science.abd0831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0831</ArticleId><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Emary K.R.W., Golubchik T., Aley P.K., Ariani C.V., Angus B., Bibi S., Blane B., Bonsall D., Cicconi P., Charlton S., et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351&#x2013;1362. doi: 10.1016/S0140-6736(21)00628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00628-0</ArticleId><ArticleId IdType="pmc">PMC8009612</ArticleId><ArticleId IdType="pubmed">33798499</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch D.H., Stephenson K.E., Sadoff J., Yu J., Chang A., Gebre M., McMahan K., Liu J., Chandrashekar A., Patel S., et al. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N. Engl. J. Med. 2021;385:951&#x2013;953. doi: 10.1056/NEJMc2108829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2108829</ArticleId><ArticleId IdType="pmc">PMC8314733</ArticleId><ArticleId IdType="pubmed">34260834</ArticleId></ArticleIdList></Reference><Reference><Citation>Gushchin V.A., Dolzhikova I.V., Shchetinin A.M., Odintsova A.S., Siniavin A.E., Nikiforova M.A., Pochtovyi A.A., Shidlovskaya E.V., Kuznetsova N.A., Burgasova O.A., et al. Neutralizing activity of sera from sputnik V-vaccinated people against variants of concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow endemic SARS-CoV-2 Variants. Vaccines. 2021;9:779. doi: 10.3390/vaccines9070779.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9070779</ArticleId><ArticleId IdType="pmc">PMC8310330</ArticleId><ArticleId IdType="pubmed">34358195</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi S.A., Baillie V., Cutland C.L., Voysey M., Koen A.L., Fairlie L., Padayachee S.D., Dheda K., Barnabas S.L., Bhorat Q.E., et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 2021;384:1885&#x2013;1898. doi: 10.1056/NEJMoa2102214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102214</ArticleId><ArticleId IdType="pmc">PMC7993410</ArticleId><ArticleId IdType="pubmed">33725432</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer A.J., Morris S., Ulaszewska M., Powers C., Kailath R., Bissett C., Truby A., Thakur N., Newman J., Allen E.R., et al. The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 B.1.351 and other variants of concern in preclinical studies. bioRxiv. 2021 doi: 10.1101/2021.06.08.447308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.08.447308</ArticleId><ArticleId IdType="pmc">PMC8881183</ArticleId><ArticleId IdType="pubmed">35228013</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada T., Zhou H., Samanovic M.I., Dcosta B.M., Cornelius A., Mulligan M.J., Landau N.R. Comparison of neutralizing antibody titers elicited by mRNA and adenoviral vector vaccine against SARS-CoV-2 variants. bioRxiv. 2021 doi: 10.1101/2021.07.19.452771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.19.452771</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaxman A., Marchevsky N., Jenkin D., Aboagye J., Aley P.K., Angus B.J., Belij-Rammerstorfer S., Bibi S., Bittaye M., Cappuccini F., et al. Tolerability and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 (AZD1222) Lancet. 2021 doi: 10.2139/ssrn.3873839. Preprint.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3873839</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd8;stergaard S.D., Schmidt M., Horv&#xe1;th-Puh&#xf3; E., Thomsen R.W., S&#xf8;rensen H.T. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: Side-effect or coincidence. Lancet. 2021;397:1441&#x2013;1443. doi: 10.1016/S0140-6736(21)00762-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00762-5</ArticleId><ArticleId IdType="pmc">PMC8009607</ArticleId><ArticleId IdType="pubmed">33798498</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalska M.A., Rauova L., Poncz M. Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. Thromb. Res. 2010;125:292&#x2013;296. doi: 10.1016/j.thromres.2009.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2009.11.023</ArticleId><ArticleId IdType="pubmed">20004006</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med. 2021;384:2092&#x2013;2101. doi: 10.1056/NEJMoa2104840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104840</ArticleId><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M., Singh D., Lown R., Poles A., Solomon T., Levi M., Goldblatt D., Kotoucek P., Thomas W., Lester W. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 2021;384:2202&#x2013;2211. doi: 10.1056/NEJMoa2105385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105385</ArticleId><ArticleId IdType="pmc">PMC8112532</ArticleId><ArticleId IdType="pubmed">33861525</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz N.H., S&#xf8;rvoll I.H., Michelsen A.E., Munthe L.A., Lund-Johansen F., Ahlen M.T., Wiedmann M., Aamodt A.-H., Skatt&#xf8;r T.H., Tj&#xf8;nnfjord G.E., et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 2021;384:2124&#x2013;2130. doi: 10.1056/NEJMoa2104882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104882</ArticleId><ArticleId IdType="pmc">PMC8112568</ArticleId><ArticleId IdType="pubmed">33835768</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker A.T., Boyd R.J., Sarkar D., Vant J., Crespo A.T., Waraich K., Truong C.D., Bates E., Wilson E., Chan C.K., et al. The Structure of ChAdOx1/AZD-1222 Reveals Interactions with CAR and PF4 with Implications for Vaccine-induced Immune Thrombotic Thrombocytopenia. bioRxiv. 2021 doi: 10.1101/2021.05.19.444882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.19.444882</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. AstraZeneca vaccine: Blood clots are "extremely rare&#x2019;&#x2019; and benefits outweigh risks, regulators conclude. BMJ. 2021;373:n931. doi: 10.1136/bmj.n931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n931</ArticleId><ArticleId IdType="pubmed">33832929</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir K.-L., Kallam A., Koepsell S.A., Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N. Engl. J. Med. 2021;384:1964&#x2013;1965. doi: 10.1056/NEJMc2105869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2105869</ArticleId><ArticleId IdType="pmc">PMC8063883</ArticleId><ArticleId IdType="pubmed">33852795</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.-J., Cines D.B., Gernsheimer T., Kessler C., Michel M., Tarantino M.D., Semple J.W., Arnold D.M., Godeau B., Lambert M.P., et al. Thrombocytopenia following pfizer and moderna SARS-CoV-2 vaccination. Am. J. Hematol. 2021;96:534&#x2013;537. doi: 10.1002/ajh.26132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26132</ArticleId><ArticleId IdType="pmc">PMC8014568</ArticleId><ArticleId IdType="pubmed">33606296</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q., Mao Q., An C., Zhang J., Gao F., Bian L., Li C., Liang Z., Xu M., Wang J. Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg. Microbes Infect. 2021;10:629&#x2013;637. doi: 10.1080/22221751.2021.1902245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1902245</ArticleId><ArticleId IdType="pmc">PMC8009122</ArticleId><ArticleId IdType="pubmed">33691606</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw R.H., Stuart A., Greenland M., Liu X., Van-Tam J.S.N., Snape M.D. Heterologous prime-boost COVID-19 vaccination: Initial reactogenicity data. Lancet. 2021;397:2043&#x2013;2046. doi: 10.1016/S0140-6736(21)01115-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01115-6</ArticleId><ArticleId IdType="pmc">PMC8115940</ArticleId><ArticleId IdType="pubmed">33991480</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Shaw R.H., Stuart A.S.V., Greenland M., Aley P.K., Andrews N.J., Cameron J.C., Charlton S., Clutterbuck E.A., Ramasamy M.N., et al. Safety and immunogenicity report from the Com-COV study&#x2014;A single-blind randomised non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. Lancet. :2021. doi: 10.2139/ssrn.3874014. Preprint.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3874014</ArticleId><ArticleId IdType="pmc">PMC8346248</ArticleId><ArticleId IdType="pubmed">34370971</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control Partial COVID-19 Vaccination, Vaccination Following SARS-CoV-2 Infection and Heterologous Vaccination Schedule: Summary of Evidence. ECDC. 2021 doi: 10.1787/23f2c52b-en.</Citation><ArticleIdList><ArticleId IdType="doi">10.1787/23f2c52b-en</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber R.I., Bender J.K., Werner G., Noll I., Sin M.A. Epidemiologisches Bulletin 25/2021. robert koch institut; Berlin, Germany: 2021. RKI.</Citation></Reference><Reference><Citation>Tanriover M.D., Do&#x11f;anay H.L., Akova M., G&#xfc;ner H.R., Azap A., Akhan S., K&#xf6;se &#x15e;., Erdin&#xe7; F.S., Akal&#x131;n E.H., Tabak &#xd6;.F., et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213&#x2013;222. doi: 10.1016/S0140-6736(21)01429-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01429-X</ArticleId><ArticleId IdType="pmc">PMC8266301</ArticleId><ArticleId IdType="pubmed">34246358</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Zhang Q., Ge J., Ren W., Zhang R., Lan J., Ju B., Su B., Yu F., Chen P., et al. Analysis of SARS-CoV-2 Variant Mutations Reveals Neutralization Escape Mechanisms and the Ability to Use ACE2 Receptors from Additional Species. Immunity. 2021;54:1611&#x2013;1621.e5. doi: 10.1016/j.immuni.2021.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.06.003</ArticleId><ArticleId IdType="pmc">PMC8185182</ArticleId><ArticleId IdType="pubmed">34166623</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kaabi N., Zhang Y., Xia S., Yang Y., Al Qahtani M.M., Abdulrazzaq N., Nusair M.A., Hassany M., Jawad J.S., Abdalla J.A., et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial. JAMA. 2021;326:35&#x2013;45. doi: 10.1001/jama.2021.8565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.8565</ArticleId><ArticleId IdType="pmc">PMC8156175</ArticleId><ArticleId IdType="pubmed">34037666</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav P.D., Ella R., Kumar S., Patil D.R., Mohandas S., Shete A.M., Vadrevu K.M., Bhati G., Sapkal G., Kaushal H., et al. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat. Commun. 2021;12:1386. doi: 10.1038/s41467-021-21639-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21639-w</ArticleId><ArticleId IdType="pmc">PMC7925524</ArticleId><ArticleId IdType="pubmed">33654090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ella R., Reddy S., Blackwelder W., Potdar V., Yadav P., Sarangi V., Aileni V.K., Kanungo S., Rai S., Reddy P., et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): A, double-blind, randomised, controlled phase 3 trial. medRxiv. 2021 doi: 10.1101/2021.06.30.21259439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.30.21259439</ArticleId><ArticleId IdType="pmc">PMC8584828</ArticleId><ArticleId IdType="pubmed">34774196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman M.J., Patel N., Guebre-Xabier M., Zhu A., Atyeo C., Pullen K.M., Loos C., Goez-Gazi Y., Carrion R., Tian J.-H., et al. Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M&#x2122; vaccination. bioRxiv. 2021 doi: 10.1101/2021.02.05.429759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.05.429759</ArticleId><ArticleId IdType="pmc">PMC8405506</ArticleId><ArticleId IdType="pubmed">34485950</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath P.T., Galiza E.P., Baxter D.N., Boffito M., Browne D., Burns F., Chadwick D.R., Clark R., Cosgrove C., Galloway J., et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 2021 doi: 10.1056/NEJMoa2107659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107659</ArticleId><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kondor R.J.G., Chung J.R., Zimmerman R.K., Nowalk M.P., Jackson M.L., Jackson L.A., Monto A.S., Martin E.T., Belongia E.A., et al. Effect of antigenic drift on influenza vaccine effectiveness in the United States&#x2014;2019-2020. Clin Infect Dis. 2020:ciaa1884. doi: 10.1093/cid/ciaa1884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1884</ArticleId><ArticleId IdType="pmc">PMC8664438</ArticleId><ArticleId IdType="pubmed">33367650</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi S.A., Polack F.P., Piedra P.A., Munoz F.M., Trenholme A.A., Sim&#xf5;es E.A., Swamy G.K., Agrawal S., Ahmed K., August A., et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N. Engl. J. Med. 2020;383:426&#x2013;439. doi: 10.1056/NEJMoa1908380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1908380</ArticleId><ArticleId IdType="pmc">PMC7299433</ArticleId><ArticleId IdType="pubmed">32726529</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J., Ariff S., Gunier R.B., Thiruvengadam R., Rauch S., Kholin A., Roggero P., Prefumo F., do Vale M.S., Cardona-Perez G.A., et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175:817&#x2013;826. doi: 10.1001/jamapediatrics.2021.1050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2021.1050</ArticleId><ArticleId IdType="pmc">PMC8063132</ArticleId><ArticleId IdType="pubmed">33885740</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray K.J., Bordt E.A., Atyeo C., Deriso E., Akinwunmi B., Young N., Baez A.M., Shook L.L., Cvrk D., James K., et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: A cohort study. Am. J. Obstet. Gynecol. 2021 doi: 10.1016/j.ajog.2021.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2021.03.023</ArticleId><ArticleId IdType="pmc">PMC7997025</ArticleId><ArticleId IdType="pubmed">33775692</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro T.T., Kim S.Y., Myers T.R., Moro P.L., Oduyebo T., Panagiotakopoulos L., Marquez P.L., Olson C.K., Liu R., Chang K.T., et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N. Engl. J. Med. 2021;384:2273&#x2013;2282. doi: 10.1056/NEJMoa2104983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104983</ArticleId><ArticleId IdType="pmc">PMC8117969</ArticleId><ArticleId IdType="pubmed">33882218</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck R.W., Klein N.P., Kitchin N., Gurtman A., Absalon J., Lockhart S., Perez J.L., Walter E.B., Senders S., Bailey R., et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N. Engl. J. Med. 2021;385:239&#x2013;250. doi: 10.1056/NEJMoa2107456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107456</ArticleId><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Comas-Herrera A., Zalaka&#xed;n J., Lemmon E., Henderson D., Litwin C., Hsu A.T., Schmidt A.E., Arling G., Fern&#xe1;ndez J.-L. Mortality Associated with COVID-19 in Care Homes: International Evidence. International Long-Term Care Policy Network, CPEC-LSE. 2020.  [(accessed on 14 October 2020)].  Available online:  LTCcovid.org.</Citation></Reference><Reference><Citation>Gustafson C.E., Kim C., Weyand C.M., Goronzy J.J. Influence of immune aging on vaccine responses. J. Allergy Clin. Immunol. 2020;145:1309&#x2013;1321. doi: 10.1016/j.jaci.2020.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.03.017</ArticleId><ArticleId IdType="pmc">PMC7198995</ArticleId><ArticleId IdType="pubmed">32386655</ArticleId></ArticleIdList></Reference><Reference><Citation>Moustsen-Helms I.R., Emborg H.-D., Nielsen J., Nielsen K.F., Krause T.G., M&#xf8;lbak K., M&#xf8;ller K.L., Berthelsen A.-S.N., Valentiner-Branth P. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers&#x2014;A Danish cohort study. medRxiv. 2021 doi: 10.1101/2021.03.08.21252200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.08.21252200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadire S.R., Wachter R.M., Lurie N. Delayed second dose versus standard regimen for Covid-19 vaccination. N. Engl. J. Med. 2021;384:e28. doi: 10.1056/NEJMclde2101987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMclde2101987</ArticleId><ArticleId IdType="pubmed">33596347</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xfc;ssow H. COVID-19: Vaccination Problems. Environ. Microbiol. 2021;23:2878&#x2013;2890. doi: 10.1111/1462-2920.15549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1462-2920.15549</ArticleId><ArticleId IdType="pmc">PMC8209888</ArticleId><ArticleId IdType="pubmed">33928745</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Brufau S., Chopra A., Ryu A.J., Gel E., Raskar R., Kremers W., Anderson K.S., Subramanian J., Krishnamurthy B., Singh A., et al. Public Health Impact of Delaying Second Dose of BNT162b2 or mRNA-1273 Covid-19 Vaccine: Simulation Agent Based Modeling Study. BMJ. 2021;373:n1087. doi: 10.1136/bmj.n1087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1087</ArticleId><ArticleId IdType="pmc">PMC8114182</ArticleId><ArticleId IdType="pubmed">33980718</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadas S.M., Vilches T.N., Zhang K., Nourbakhsh S., Sah P., Fitzpatrick M.C., Galvani A.P. Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biol. 2021;19:e3001211. doi: 10.1371/journal.pbio.3001211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001211</ArticleId><ArticleId IdType="pmc">PMC8092656</ArticleId><ArticleId IdType="pubmed">33882066</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry H., Bruton R., Stephens C., Brown K., Amirthalingam G., Hallis B., Otter A., Zuo J., Moss P. Extended interval BNT162b2 Vaccination Enhances Peak Antibody Generation in Older People. medRxiv. 2021 doi: 10.1101/2021.05.15.21257017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.15.21257017</ArticleId><ArticleId IdType="pmc">PMC8795435</ArticleId><ArticleId IdType="pubmed">35087066</ArticleId></ArticleIdList></Reference><Reference><Citation>GOV.IL  Decline in Vaccine Effectiveness Against Infection and Symptomatic Illness.  [(accessed on 20 August 2021)];2021  Available online:  https://www.gov.il/en/departments/news/05072021-03.</Citation></Reference><Reference><Citation>Biontech. Pfizer und BioNTech Geben vor dem Hintergrund der Delta-Variante ein Update zu Ihrem Auffrischungsimpfungen-Programm Bekannt. Biontech. 2021.  [(accessed on 8 July 2021)].  Available online:  https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-geben-vor-dem-hintergrund-der-delta-variante/</Citation></Reference><Reference><Citation>Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: An overview. Diabetes Metab. Syndr. 2021;15:869&#x2013;875. doi: 10.1016/j.dsx.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Milne A., Samms E., Stadon L., Maskell N.A., Hamilton F.W. Are vaccines safe in patients with Long COVID? A prospective observational study. medRxiv. 2021 doi: 10.1101/2021.03.11.21253225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.11.21253225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherwood O., Strain D.W., Rossman J., The Impact of COVID Vaccination on Symptoms of Long Covid  An International Survey of 900 People with Lived Experience (May 2021) Patient Safety Learning&#x2014;The Hub. 2021.  [(accessed on 26 August 2021)].  Available online:  https://www.pslhub.org/learn/coronavirus-covid19/data-and-statistics/the-impact-of-covid-vaccination-on-symptoms-of-long-covid-an-international-survey-of-900-people-with-lived-experience-may-2021-r4636/</Citation></Reference><Reference><Citation>Mishra P.K., Bruiners N., Ukey R., Datta P., Onyuka A., Handler D., Hussain S., Honnen W., Singh S., Guerrini V., et al. Vaccination Boosts Protective Responses and Counters SARS-CoV-2-Induced Pathogenic Memory B Cells. medRxiv. 2021 doi: 10.1101/2021.04.11.21255153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.11.21255153</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B., Mohn K.G.-I., Brokstad K.A., Zhou F., Linchausen D.W., Hansen B.-A., Lartey S., Onyango T.B., Kuwelker K., S&#xe6;vik M., et al. Long COVID in a Prospective Cohort of Home-Isolated Patients. Nat. Med. 2021;27:1607&#x2013;1613. doi: 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  COVID-19 Breakthrough Case Investigations and Reporting|CDC.  [(accessed on 20 August 2021)]; Available online:  https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html.</Citation></Reference><Reference><Citation>Robert Koch-Institut. W&#xf6;chentlicher Lagebericht des RKI vom 22.07.2021. RKI. 2021.  [(accessed on 22 July 2021)].  Available online:  https://www.rki.de.</Citation></Reference><Reference><Citation>Brosh-Nissimov T., Orenbuch-Harroch E., Chowers M., Elbaz M., Nesher L., Stein M., Maor Y., Cohen R., Hussein K., Weinberger M., et al. BNT162b2 Vaccine Breakthrough: Clinical Characteristics of 152 Fully Vaccinated Hospitalized COVID-19 Patients in Israel. Clin Microbiol Infect. 2021:S1198-743X(21)00367-0. doi: 10.1016/j.cmi.2021.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.06.036</ArticleId><ArticleId IdType="pmc">PMC8261136</ArticleId><ArticleId IdType="pubmed">34245907</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacisuleyman E., Hale C., Saito Y., Blachere N.E., Bergh M., Conlon E.G., Schaefer-Babajew D.J., DaSilva J., Muecksch F., Gaebler C., et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N. Engl. J. Med. 2021;384:2212&#x2013;2218. doi: 10.1056/NEJMoa2105000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105000</ArticleId><ArticleId IdType="pmc">PMC8117968</ArticleId><ArticleId IdType="pubmed">33882219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kustin T., Harel N., Finkel U., Perchik S., Harari S., Tahor M., Caspi I., Levy R., Leshchinsky M., Dror S.K., et al. Evidence for Increased Breakthrough Rates of SARS-CoV-2 Variants of Concern in BNT162b2 mRNA Vaccinated Individuals. Nat. Med. 2021;27:1379&#x2013;1384. doi: 10.1038/s41591-021-01413-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01413-7</ArticleId><ArticleId IdType="pmc">PMC8363499</ArticleId><ArticleId IdType="pubmed">34127854</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrotri M., Swinnen T., Kampmann B., Parker E.P.K. An Interactive Website Tracking COVID-19 Vaccine Development. Lancet Glob. Health. 2021;9:e590&#x2013;e592. doi: 10.1016/S2214-109X(21)00043-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00043-7</ArticleId><ArticleId IdType="pmc">PMC8049589</ArticleId><ArticleId IdType="pubmed">33667404</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes G.M., Motta F., Sasaki L.M.P., Da Silva &#xc2;.P., Miranda A.M., De Carvalho A.O., Gomides A.P.M., Soares A.A.D.S.M., Dos Santos A.D.C.M., Jr., Alves C.D.O., et al. Pregnancy outcomes and child development effects of SARS-CoV-2 infection (PROUDEST trial): Protocol for a multicenter, prospective cohort study. JMIR Res. Protoc. 2021;10:e26477. doi: 10.2196/26477.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/26477</ArticleId><ArticleId IdType="pmc">PMC8059788</ArticleId><ArticleId IdType="pubmed">33793409</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak A., Adegboye O.A., Adekunle A.I., Rahman K.M., McBryde E.S., Eisen D.P. Economic Consequences of the COVID-19 Outbreak: The Need for Epidemic Preparedness. Front. Public Health. 2020;8:241. doi: 10.3389/fpubh.2020.00241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.00241</ArticleId><ArticleId IdType="pmc">PMC7273352</ArticleId><ArticleId IdType="pubmed">32574307</ArticleId></ArticleIdList></Reference><Reference><Citation>Faulkner N., Ng K.W., Wu M.Y., Harvey R., Margaritis M., Paraskevopoulou S., Houlihan C., Hussain S., Greco M., Bolland W., et al. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. eLife. 2021;10 doi: 10.7554/eLife.69317.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.69317</ArticleId><ArticleId IdType="pmc">PMC8352583</ArticleId><ArticleId IdType="pubmed">34323691</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyo-Gwete T., Madzivhandila M., Makhado Z., Ayres F., Mhlanga D., Oosthuysen B., Lambson B.E., Kgagudi P., Tegally H., Iranzadeh A., et al. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. bioRxiv. 2021 doi: 10.1101/2021.03.06.434193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.06.434193</ArticleId><ArticleId IdType="pmc">PMC8063886</ArticleId><ArticleId IdType="pubmed">33826816</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbison A.M., Fogarty C.A., Phung T.K., Satheesan A., Schulz B.L., Fadda E. Fine-tuning the Spike: Role of the nature and topology of the glycan shield in the structure and dynamics of SARS-CoV-2 S. bioRxiv. 2021 doi: 10.1101/2021.04.01.438036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.01.438036</ArticleId><ArticleId IdType="pmc">PMC8729800</ArticleId><ArticleId IdType="pubmed">35126971</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed C.C., Schultheis K., Andrade V.M., Kalia R., Tur J., Schouest B., Elwood D., Walters J.N., Maricic I., Doan A., et al. Design, immunogenicity and efficacy of a Pan-SARS-CoV-2 synthetic DNA vaccine. bioRxiv. 2021 doi: 10.1101/2021.05.11.443592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.11.443592</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce M.G., King H.A.D., Naouar I.E., Ahmed A., Peachman K.K., Cincotta C.M., Subra C., Chen R.E., Thomas P.V., Chen W.-H., et al. Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates. bioRxiv. 2021 doi: 10.1101/2021.03.24.436523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.24.436523</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders K.O., Lee E., Parks R., Martinez D.R., Li D., Chen H., Edwards R.J., Gobeil S., Barr M., Mansouri K., et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021;594:553&#x2013;559. doi: 10.1038/s41586-021-03594-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03594-0</ArticleId><ArticleId IdType="pmc">PMC8528238</ArticleId><ArticleId IdType="pubmed">33971664</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Zeng J., Li R., Wen Z., Cai Y., Wallin J., Shu Y., Du X., Sun C. Rational Design of a Pan-Coronavirus Vaccine Based on Conserved CTL Epitopes. Viruses. 2021;13:333. doi: 10.3390/v13020333.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020333</ArticleId><ArticleId IdType="pmc">PMC7926959</ArticleId><ArticleId IdType="pubmed">33670023</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>